New Delhi: The Delhi High Court on Wednesday heard a PIL, to set aside the permission granted by the Drugs Controller General of India to Bharat Biotech for conducting the phase II/III clinical trial of its Covaxin COVID-19 vaccine on the 2-18 age group.
A bench of Chief Justice D N Patel and Justice Jyoti Singh issued notice to the Centre and Bharat Biotech seeking their stand by July 15 on the petition, said media reports.
The court declined to pass any interim order staying the permission, granted on May 12, for clinical trials as sought by the petitioner, Sanjeev Kumar. The trial will be conducted on 525 healthy volunteers. In the trial, the vaccine will be given by intramuscular route in two doses, on day 0 and day 28, News18 reported.
Covaxin, which has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India’s ongoing COVID-19 vaccination drive.
New Delhi: The verbal duel between Trinamool Congress (TMC) and Bharatiya Janata Party (BJP) escalated…
New Delhi: A day after Delhi Chief Minister Arvind Kejriwal's ED remand was extended till…
Bhubaneswar: Odisha is likely to experience hot and humid weather conditions during the next 4-5…
New Delhi: In another blow to cash-strapped Congress ahead of the Lok Sabha polls, the…
New Delhi: The Central Bureau of Investigation (CBI) has filed a closure report in the…
Bhubaneswar: A day after resigning from Congress, former minister Surendra Singh Bhoi on Friday joined…
Bhubaneswar: Hours after BJP Cuttack district president Prakash Chandra Behera quit BJP, two-time MLA from…
Bhubaneswar: The ruling BJD and the main opposition BJP are likely to announce their third…